|
1
|
Kumar SS, Tomita Y, Wrin J, Bruhn M, Swalling A, Mohammed M, Price TJ, Hardingham JE. High early growth response 1 (EGR1) expression correlates with resistance to anti-EGFR treatment in vitro and with poorer outcome in metastatic colorectal cancer patients treated with cetuximab. Clin Transl Oncol 2016; 19:718-726. [DOI: 10.1007/s12094-016-1596-8] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2016] [Accepted: 12/10/2016] [Indexed: 01/30/2023]
|
|
2
|
Kumar SS, Price TJ, Townsend AR, Hocking C, Hardingham JE. Predictive biomarkers of response to anti-EGF receptor monoclonal antibody therapies. COLORECTAL CANCER 2014. [DOI: 10.2217/crc.14.3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
SUMMARY The EGF receptor (EGFR) pathway plays an important role in the progression of several carcinomas, including colorectal cancer (CRC). The EGFR has emerged as a candidate for targeted therapy for CRC. Two monoclonal antibodies used to inhibit the EGFR signaling pathway are cetuximab and panitumumab. Both these monoclonal antibodies inhibit tumor-promoting activities, such as tumor cell proliferation, survival, angiogenesis and metastasis. However, only a subpopulation of metastatic CRC patients responds to such therapy. Constitutive activation within the pathway gives rise to other aberrantly expressed biomarkers that are able to circumvent the anti-EGFR treatment and confer resistance. Mechanisms of resistance and the value of these emerging predictive biomarkers in the clinical setting are discussed in this review.
Collapse
Affiliation(s)
- Shalini Sree Kumar
- Hematology–Oncology Department, Basil Hetzel Institute for Translational Health Research, The Queen Elizabeth Hospital, Woodville, SA 5011, Australia
- Department of Physiology, School of Medical Sciences, University of Adelaide, SA 5005, Australia
| | - Timothy J Price
- Medical Oncology Unit, The Queen Elizabeth Hospital, Woodville, SA 5011, Australia
- School of Medicine, University of Adelaide, Adelaide, SA 5005, Australia
| | - Amanda R Townsend
- Medical Oncology Unit, The Queen Elizabeth Hospital, Woodville, SA 5011, Australia
| | - Christopher Hocking
- Medical Oncology Unit, The Queen Elizabeth Hospital, Woodville, SA 5011, Australia
| | - Jennifer E Hardingham
- Hematology–Oncology Department, Basil Hetzel Institute for Translational Health Research, The Queen Elizabeth Hospital, Woodville, SA 5011, Australia
- Department of Physiology, School of Medical Sciences, University of Adelaide, SA 5005, Australia
| |
Collapse
|